Janux Therapeutics (NASDAQ:JANX) Earns Peer Perform Rating from Analysts at Wolfe Research

Wolfe Research began coverage on shares of Janux Therapeutics (NASDAQ:JANX) in a report issued on Tuesday. The brokerage set a “peer perform” rating on the stock.

Other analysts have also recently issued research reports about the stock. Wedbush reiterated an “outperform” rating and issued a $76.00 price objective on shares of Janux Therapeutics in a research note on Friday, November 7th. Stifel Nicolaus reiterated a “buy” rating and set a $45.00 price target on shares of Janux Therapeutics in a research report on Wednesday, September 10th. Piper Sandler initiated coverage on Janux Therapeutics in a research note on Monday, August 18th. They set an “overweight” rating and a $42.00 price target on the stock. Truist Financial initiated coverage on Janux Therapeutics in a research note on Wednesday, September 10th. They issued a “buy” rating and a $100.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $79.17.

Janux Therapeutics Price Performance

Janux Therapeutics stock opened at $28.72 on Tuesday. The stock’s 50 day moving average price is $25.69 and its 200 day moving average price is $25.03. Janux Therapeutics has a 1-year low of $21.73 and a 1-year high of $71.71. The company has a market cap of $1.73 billion, a PE ratio of -17.10 and a beta of 2.83.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.21. The business had revenue of $10.00 million during the quarter, compared to analyst estimates of $3.07 million. On average, equities research analysts anticipate that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

Insider Buying and Selling at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 16,665 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $30.06, for a total value of $500,949.90. Following the transaction, the insider owned 82,139 shares in the company, valued at approximately $2,469,098.34. This trade represents a 16.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 29.40% of the stock is owned by corporate insiders.

Institutional Trading of Janux Therapeutics

Several large investors have recently bought and sold shares of JANX. US Bancorp DE increased its stake in Janux Therapeutics by 2,402.9% during the 1st quarter. US Bancorp DE now owns 1,727 shares of the company’s stock worth $47,000 after buying an additional 1,658 shares during the period. Osaic Holdings Inc. grew its stake in Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after purchasing an additional 3,037 shares in the last quarter. Virtus Investment Advisers LLC increased its holdings in Janux Therapeutics by 37.9% during the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after purchasing an additional 1,011 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Janux Therapeutics by 175.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after purchasing an additional 2,502 shares during the last quarter. Finally, Ameritas Investment Partners Inc. raised its position in shares of Janux Therapeutics by 25.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after purchasing an additional 820 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.